Ordastobart

Monoclonal antibody

Also known as INBRX-106, ES102

Earlyevidence

Evidence outlook

Mid-stage readout reported

A Phase 2/3 readout has been reported. The trial rows below carry the recorded result.

Latest reported trial: HexAgon-HN (NCT06295731) · Phase 2/3 · met primary endpoint · grade pending

Also in development:Non-Small Cell Lung Cancer · Phase 2

Company guidance: data expected mid-2027 (Inhibrx Biosciences, Inc, 13 Nov 2026). “The Company expects initial results from its Phase 1/2 study of ordastobart (INBRX-106) in the perioperative setting of non-small cell lung cancer (NSCLC) in mid-2027.” Source ↗

The company’s own stated timing, shown beside the ClinicalTrials.gov estimate. Neither is a confirmed date.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 2/3 (1)
Head and Neck Squamous Cell Carcinoma
Phase 2 (2)
Non-Small Cell Lung Cancer
Other / comorbidity
NCT06353997 · Providence Health & Services
2024-09-05 – 2029-06 · Triple Negative Breast Cancer
What this study did
Phase 1/2 (1)
Head and Neck Squamous Cell Carcinoma
Phase 1 (2)
Other / comorbidity
NCT04991506 · Elpiscience Biopharma, Ltd.
2021-10-15 – 2024-05-17 · Solid Tumor, Neoplasms, Malignant Tumor
What this study did
NCT04730843 · Elpiscience Biopharma, Ltd.
2021-04-01 – 2024-03-01 · Solid Tumors, Neoplasms, Malignant Tumor
What this study did

Competitive landscape

1 other tracked programme targets this mechanism, none of them ahead of this one.

This drug's own stage for Head and Neck Squamous Cell Carcinoma: Phase 2/3. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Ordastobart: this drugPhase 2/3Monoclonal antibodyOX40 (agonist)not yet gradedNo reviewed efficacy summary in this indication
CetuximabApprovedMonoclonal antibodyEGFRPartial signal
NCT00122460: Overall Survival Time (OS) (time from randomization to death or last day known to be alive, reported between day of first patient randomised, 21 Dec 2004, until cut-off date 12 Mar 2007): Cetuximab Plus Chemotherapy 10.1 months (95% CI 8.6 to 11.2) | Chemotherapy Alone 7.4 months (95% CI 6.4 to 8.3)
Docetaxel (Taxotere)ApprovedSmall moleculeMicrotubules (tubulin)not yet gradedNo reviewed efficacy summary in this indication
NivolumabApprovedMonoclonal antibodyPD-1Partial signal
NCT02105636: Overall Survival (OS) (From date of randomization to date of death (Up to approximately 18 months)): Nivolumab 3mg/kg 7.49 Months (95% CI 5.49 to 9.1) | Investigators Choice 5.06 Months (95% CI 4.04 to 6.05)
Opdivo QvantigApprovedMonoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
PembrolizumabApprovedMonoclonal antibodyPD-1Partial signal
NCT02358031: Primary endpoint, overall survival at a pre-specified interim analysis: pembrolizumab plus platinum/fluorouracil vs cetuximab plus platinum/fluorouracil, median 13.0 vs 10.7 months, HR 0.77; pembrolizumab alone vs cetuximab-chemotherapy in PD-L1 CPS >=1, HR 0.65 (95% CI 0.53 to 0.80) (KEYTRUDA label, KEYNOTE-048).
Rybrevant Faspro (amivantamab And Hyaluronidase-Lpuj)ApprovedMultispecific antibodyEGFR x c-METnot yet gradedNo reviewed efficacy summary in this indication
AmivantamabPhase 3Multispecific antibodyEGFR x c-METnot yet gradedNo reviewed efficacy summary in this indication
CPO301Phase 3Antibody–drug conjugateEGFRnot yet gradedNo reviewed efficacy summary in this indication
NBTXR3Phase 3NanoparticleHafnium-oxide nanoparticle radioenhancernot yet gradedNo reviewed efficacy summary in this indication
VolrustomigPhase 3Multispecific antibodyPD-1 x CTLA-4not yet gradedNo reviewed efficacy summary in this indication
IzalontamabPhase 2Multispecific antibodyEGFR + HER3not yet gradedNo reviewed efficacy summary in this indication
Ozuriftamab VedotinPhase 2Antibody–drug conjugateROR2Partial signalNo reviewed efficacy summary in this indication
ALE.P02Phase 1/2Antibody–drug conjugateClaudin-1 (CLDN1)not yet gradedNo reviewed efficacy summary in this indication
PepinemabPhase 1/2Monoclonal antibodySEMA4Dnot yet gradedNo reviewed efficacy summary in this indication
BuparlisibDiscontinuedSmall moleculePI3K inhibitor (pan-class I)not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(4 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Ordastobart to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (2)
February 2027 (1)
Phase 2Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2027-02-28 · NCT06623136 · CT.gov ↗
What to watch
June 2027 (1)
Phase 2Triple Negative Breast CancerRecruiting
Est. primary completion 2027-06 · NCT06353997 · CT.gov ↗
What to watch
2029 (1)
December 2029 (1)
Phase 2/3Head and Neck Squamous Cell CarcinomaRecruiting
Est. primary completion 2029-12 · NCT06295731 · CT.gov ↗
What to watch
2033 (1)
July 2033 (1)
Phase 1/2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2033-07 · NCT04198766 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

8 September 2026Topline resultPhase 2 portion of NCT06295731: INBRX-106 + pembrolizumab confirmed ORR 48.3% vs 26.5% (primary endpoint analysis)
Inhibrx Biosciences · Source ↗